FDA Supports More Focused Development of Targeted Pain Therapies

11 September 2018

Jill Wechsler / Pharmaceutical Executive

To help combat the nation’s opioid epidemic, FDA is promoting a more tailored approach to developing and testing effective analgesics, with the aim of bringing less addictive pain treatments to market more quickly. This is part of a range of strategies for reducing excessive opioid use and mis-use, while ensuring patient access to effective treatments for pain and addiction.

FDA’s latest step involves issuing a series of guidance documents that map out specific methods for developing more targeted pain and addiction treatments, including abuse-deterrent opioid formulations and analgesics with low- or no-opioid formulations. To set the stage, FDA is withdrawing a 2014 draft guidance on developing drugs and biologics with analgesic indications, explained FDA commissioner Scott Gottlieb in a recent statement. The old advisory will be replaced by at least four new guidances in the coming year that aim to shift sponsors away from development programs with multiple large studies designed to support new products with broad indications for treating general chronic pain. 

The new advisories will recommend that sponsors study one or two populations with an eye to gaining more expeditious approval of drugs or biologics that treat specific kinds of pain in certain patients. An initial guidance will encourage using this approach in developing low-opioid pain therapies that “demonstrate clinically meaningful reduction” in exposing patients to opioids in treating acute pain. Another document will provide a new framework for evaluating risks associated with the intentional misuse or abuse of new opioid therapies. A third guidance will support the development of extended-release local anesthetics to replace oral systemic opioids in certain situations. And the agency will further advise on developing non-opioid pain therapies to provide safer long-term treatment of chronic pain. 

All these strategies for developing and testing innovative pain therapies build on ongoing FDA initiatives to combat opioid abuse and misuse. FDA has strengthened and expanded its REMS (risk evaluation and mitigation strategy) for opioid drugs and has stepped up enforcement actions against online sellers of illicit opioids. Another area of innovation involves developing medical devices and mobile applications to treat pain.

FDA also has engaged the National Academics of Sciences, Engineering and Medicine (NASEM) to help develop new evidence-based guidelines for appropriate prescribing of opioids for acute pain. The aim is to help shape clinical practice and to inform drug labeling for these therapies. Many of these strategies, though, rely on physicians agreeing to prescribe low- and no-opioid medicines, and for health plans to pay for them.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more